title: [Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].
authors.forename: Olivier
authors.initials: O
authors.lastname: Lidove
authors.forename: Gabriel
authors.initials: G
authors.lastname: Choukroun
authors.forename: Soumeya
authors.initials: S
authors.lastname: Bekri
authors.forename: Géraldine
authors.initials: G
authors.lastname: Viot
authors.forename: Michel
authors.initials: M
authors.lastname: Tsimaratos
authors.forename: Dominique
authors.initials: D
authors.lastname: Joly
mesh_terms: D000293:Adolescent; D000328:Adult; D001709:Biotechnology; D004335:Drug and Narcotic Control; D056947:Enzyme Replacement Therapy; D005062:European Union; D000795:Fabry Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000600:supply & distribution / Q000627:therapeutic use; D008297:Male; D009965:Orphan Drug Production; D000519:alpha-Galactosidase / Q000600:supply & distribution / Q000627:therapeutic use*
chemical_list: D007527:Isoenzymes; D000519:alpha-Galactosidase; C459420:agalsidase beta